Effects of nocebo and drusebo in determining statin-induced muscle symptoms
https://doi.org/10.21518/2079-701X-2022-16-17-136-142
Abstract
Statins represent an important class of cardiovascular drugs for the prevention of atherogenic complications. However, despite the effectiveness of statins, non-adherence and discontinuation of therapy with these drugs is a problem worldwide. Reasons for not using statins in patients at high CV risk include statin-associated muscle symptoms (SAMS), which are not usually associated with significant elevations of serum creatine kinase. SAMS are the most common side effects of statins: 3–5% in RCTs, 15–20% in observational studies, and 60% in patient surveys. This range is possibly due to misinterpretation of symptoms, as well as patients’ expectation of harm from statin treatment (“statin fear”). The article highlights the problem of studying the role of nocebo and drusebo effects for SAMS, presents differences in definitions and methods of detection. The concept of the drucebo effect was proposed by the International Lipid Expert Group (ILEP, 2018) as a harm to the patient, unrelated to the pharmacological action of the drug (negative effect of the drucebo). The results of studies and meta-analyses evaluating the effects of nocebo and drusebo for SAMS are presented, in which no difference was found in the frequency and severity of muscle symptoms between statin and placebo; the nocebo rate was 90% of the statin effect, and the contribution of the drusebo effect to SAMS and statin discontinuation ranged from 38 to 78%. Also presented are current international guidelines and principles of patient management aimed at preventing discontinuation of statin use in connection with SAMS.
About the Author
M. V. Leonova
Moscow Regional Branch of Clinical Pharmacology Association, Interregional Non-Profit Organisation
Russian Federation
Russian Federation
Corr. Member PAEH, Dr. Sci. (Med.), Professor, Clinical Pharmacologist, Member of the Moscow Regional Branch,
50, Kommunisticheskaya St., Volgograd, 400005
References
1. Collins R., Reith C., Emberson J., Armitage J., Baigent C., Blackwell L. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561. https://doi.org/10.1016/s0140-6736(16)31357-5.
2. Chowdhury R., Khan H., Heydon E., Shroufi A., Fahimi S., Moore C. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–2948. https://doi.org/10.1093/eurheartj/eht295.
3. Thompson P.D., Panza G., Zaleski A., Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–2410. https://doi.org/10.1016/j.jacc.2016.02.071.
4. Stroes E.S., Thompson P.D., Corsini A., Vladutiu G.D., Raal F.J., Ray K.K. et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022. https://doi.org/10.1093/eurheartj/ehv043.
5. Penson P.E., Mancini G.B.J., Toth P.P., Martin S.S., Watts G.F., Sahebkar A. et al.; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP). Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9(6):1023–1033. https://doi.org/10.1002/jcsm.12344.
6. Cohen J.D., Brinton E.A., Ito M.K., Jacobson T.A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–215. https://doi.org/10.1016/j.jacl.2012.03.003.
7. Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52–60. https://doi.org/10.1016/j.amjcard.2005.12.010.
8. Manchikanti L., Boswell M.V., Kaye A.D., Helm I.S., Hirsch J.A. Therapeutic role of placebo: evolution of a new paradigm in understanding research and clinical practice. Pain Physician. 2017;20(5):363–386. 9. Nissen S.E. Statin denial: an internet‐driven cult with deadly consequences. Ann Intern Med. 2017;167:281–282. https://doi.org/10.7326/M17-1566.
9. Riaz H., Khan A.R., Khan M.S., Rehman K.A., Alansari S.A.R., Gheyath B. et al. Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol. 2017;120(5):774–781. https://doi.org/10.1016/j.amjcard.2017.05.046.
10. Herrett E., Williamson E., Brack K., Beaumont D., Perkins A., Thayne A. et al.; StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. https://doi.org/10.1136/bmj.n135.
11. Howard J.P., Wood F.A., Finegold J.A., Nowbar A.N., Thompson D.M., Arnold A.D. et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210–1222. https://doi.org/10.1016/j.jacc.2021.07.022.
12. Rosenson R.S., Baker S.K., Jacobson T.A., Kopecky S.L., Parker B.A. The National Lipid Association’s muscle safety expert panel an assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl.):S58–S71.. https://doi.org/10.1016/j.jacl.2014.03.004.
13. Rosenson R.S., Miller K., Bayliss M., Sanchez R.J., Baccara-Dinet M.T., Chibedi-De-Roche D. et al. The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179–186. https://doi.org/10.1007/s10557-017-6723-4.
14. Rallidis L.S. A practical algorithm for the management of patients with statinassociated muscle symptoms. HJC. 2020;61(2):137–140. https://doi.org/10.1016/j.hjc.2019.09.001.
15. Penson P.E., Bruckert E., Marais D., Reiner Ž., Pirro M., Sahebkar A. et al.; International Lipid Expert Panel (ILEP). Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13(3):1596–1622. https://doi.org/https://doi.org/10.1002/jcsm.12960.
16. Banach M., Mikhailidis D.P. Statin intolerance: some practical hints. Cardiol Clin. 2018;36(2):225–231. https://doi.org/10.1016/j.ccl.2017.12.004.
Review
For citations:
Leonova MV. Effects of nocebo and drusebo in determining statin-induced muscle symptoms. Meditsinskiy sovet = Medical Council. 2022;(17):136-142. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-17-136-142
Views:
503
Email this article 